Advertisement
CELC vs TMED
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a StrongBuy and TMED is a StrongBuy.
CELC's RSI Indicator climbs out of oversold territory
The RSI Indicator for CELC moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 22 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 59 cases where CELC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CELC just turned positive on October 22, 2026. Looking at past instances where CELC's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.
Following a +9.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CELC's P/B Ratio (-251.034) is very low in comparison to the industry average of (2.973). P/E Ratio (-15.249) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CELC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for TMED turns positive, indicating new upward trend
TMED saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator turned positive. In 18 of the 18 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TMED just turned positive on October 15, 2026. Looking at past instances where TMED's MACD turned positive, the stock continued to rise in 15 of 16 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMED advanced for three days, in 69 of 75 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
TMED broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
CELC | ||
|---|---|---|
OUTLOOK RATING 1..100 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 65 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 84 | |
P/E GROWTH RATING 1..100 | 17 | |
SEASONALITY SCORE 1..100 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CELC | TMED | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 76% |
| Momentum ODDS (%) | N/A | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 74% |
| Advances ODDS (%) | 1 day ago 85% | 3 days ago 90% |
| Declines ODDS (%) | 9 days ago 85% | 10 days ago 75% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CELC’s FA Score shows that 2 FA rating(s) are green while .
- CELC’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CELC’s TA Score shows that 5 TA indicator(s) are bullish.
- CELC’s TA Score: 5 bullish, 2 bearish.
Price Growth
CELC (@Biotechnology) experienced а +8.74% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
CELC is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
TMED and
Correlation & Price change
A.I.dvisor tells us that TMED and BNTX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TMED and BNTX's prices will move in lockstep.
| Ticker / NAME | Correlation To TMED | 1D Price Change % | ||
|---|---|---|---|---|
| TMED | 100% | +0.79% | ||
| BNTX - TMED | 31% Poorly correlated | -1.77% | ||
| PCVX - TMED | 22% Poorly correlated | -0.60% | ||
| SDGR - TMED | 22% Poorly correlated | -5.44% | ||
| CELC - TMED | 22% Poorly correlated | +6.51% | ||
| BIIB - TMED | 22% Poorly correlated | +5.34% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PATX | 10.68 | 0.33 | +3.19% |
| Tradr 2X Long PATH Daily ETF (PATX) | |||
| SBI | 7.29 | 0.04 | +0.55% |
| Western Asset Intermediate Muni Fund | |||
| OCTM | 34.40 | 0.01 | +0.03% |
| FT Vest U.S. Equity Max Buffer ETF - October (OCTM) | |||
| IYJ | 157.15 | -1.02 | -0.64% |
| iShares U.S. Industrials ETF (IYJ) | |||
| RGLO | 33.01 | -0.46 | -1.38% |
| Russell Investments Global Equity ETF (RGLO) | |||